{
  "id": "beta-lactam-antibiotic",
  "title": "Beta-Lactam Antibiotic",
  "lang": "en",
  "source_lang": "en",
  "summary": "A class of antibacterial drugs containing a beta-lactam ring that inhibit bacterial cell-wall synthesis, including penicillins, cephalosporins, carbapenems, and monobactams.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "β-lactam antibiotic",
    "beta-lactam antibacterial",
    "β-lactam antibacterial"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/beta-lactam-antibiotic/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/beta-lactam-antibiotic/",
      "json": "https://aiwiki.page/zh/beta-lactam-antibiotic.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Beta-lactam antibiotics are antibacterial drugs defined by a four-membered cyclic amide, the beta-lactam ring, within their molecular structure. The major therapeutic groups are penicillins, cephalosporins, carbapenems, and monobactams. They act principally by binding bacterial enzymes involved in constructing the cell wall, disrupting a structure essential to the survival of many bacteria. Their selective action reflects a fundamental biological difference: human cells do not possess the peptidoglycan cell wall targeted by these drugs.\n\nSince the introduction of penicillin in the 1940s, beta-lactams have become central to the treatment of bacterial infectious diseases and to the prevention of infection associated with many surgical procedures. The class includes narrow-spectrum agents directed mainly against particular Gram-positive organisms and broad-spectrum agents active against numerous Gram-negative pathogens. Its clinical importance is matched by the diversity of bacterial resistance mechanisms, especially beta-lactamase enzymes, altered drug targets, and reduced drug entry. Understanding the class therefore requires attention to molecular structure, bacterial physiology, drug exposure, laboratory susceptibility, and the evolution of antibiotic resistance."
    },
    {
      "heading": "Discovery and development",
      "text": "The development of beta-lactams began with the antibacterial activity of a mold contaminating a bacterial culture. In 1928, Alexander Fleming observed that a Penicillium mold inhibited nearby staphylococci; he published his findings in 1929. The observation established the existence of penicillin but did not immediately produce a practical medicine. Obtaining a stable, sufficiently pure preparation in useful quantities remained a major obstacle.\n\nAt Oxford, Howard Florey, Ernst Boris Chain, Norman Heatley, and their colleagues developed methods for extracting and testing penicillin. Animal experiments reported in 1940 demonstrated protection against otherwise lethal bacterial infection, and clinical treatment followed in 1941. Wartime collaboration between British and American researchers, government agencies, and manufacturers transformed production through strain selection and large-scale fermentation. During World War II, penicillin became available in quantities sufficient for widespread military use. Fleming, Chain, and Florey shared the 1945 Nobel Prize in Physiology or Medicine.\n\nStructural chemistry then enabled systematic expansion of the class. Dorothy Crowfoot Hodgkin’s crystallographic work established the beta-lactam-containing structure of penicillin in 1945. Identification and isolation of 6-aminopenicillanic acid, the common penicillin nucleus, during the 1950s made it possible to change side chains while retaining the active core. Semisynthetic drugs consequently acquired properties absent or limited in natural penicillin, including improved acid stability, resistance to certain bacterial enzymes, and activity against additional Gram-negative organisms.\n\nA second major lineage originated with Giuseppe Brotzu’s 1945 observations of an antibiotic-producing fungus from seawater near sewage discharge in Sardinia. Subsequent work yielded cephalosporin C and the chemical basis for semisynthetic cephalosporins. Later discoveries included cephamycins, carbapenems, and monobactams. Thienamycin, isolated from Streptomyces cattleya in the 1970s, provided the foundation for imipenem, a more usable derivative.\n\nResistance accompanied development from the outset. In 1940, Edward Abraham and Chain described an enzyme capable of destroying penicillin, before the drug entered widespread use. Successive generations of beta-lactams therefore emerged from a continuing interaction between natural-product discovery, chemical modification, industrial production, and bacterial adaptation. Newer agents did not simply replace older ones: narrow-spectrum penicillins retained important uses because particular pathogens remained susceptible and because unnecessary breadth of antibacterial activity has ecological costs."
    },
    {
      "heading": "Chemical structure and inhibition of cell-wall synthesis",
      "text": "The defining beta-lactam ring contains three carbon atoms and one nitrogen atom, with a carbonyl group adjacent to the nitrogen. Its constrained geometry makes the amide unusually reactive compared with many ordinary amides. In penicillins, the ring is fused to a five-membered sulfur-containing thiazolidine ring; in conventional cephalosporins, it is fused to a six-membered dihydrothiazine ring. Carbapenems have a different five-membered fused ring, whereas monobactams possess a beta-lactam ring without a second fused ring. Substituents around these scaffolds strongly influence antibacterial activity, stability, absorption, and elimination.\n\nThe principal target is peptidoglycan, a mesh of alternating N-acetylglucosamine and N-acetylmuramic acid sugars joined by short peptide bridges. This material supports the bacterial envelope against internal osmotic pressure. The final stages of its assembly involve penicillin-binding proteins, or PBPs, a group of enzymes that includes transpeptidases responsible for cross-linking peptide chains. Many beta-lactams act as structural and chemical mimics of elements of the normal peptide substrate.\n\nA susceptible PBP attacks the beta-lactam ring through an active-site serine residue. Ring opening produces a covalent acyl-enzyme complex that is hydrolyzed only slowly, functionally disabling the enzyme. The resulting loss of effective cross-linking disrupts cell-wall construction. Depending on which PBPs are inhibited, bacteria may elongate into filaments, become rounded or swollen, lose envelope integrity, or undergo lysis. Bacterial wall-remodeling enzymes, often called autolysins, contribute to the consequences of impaired synthesis.\n\nBeta-lactams are generally bactericidal against susceptible bacteria under conditions that permit active cell-wall synthesis. Their activity nevertheless depends on bacterial physiological state. Slowly growing organisms, stationary-phase cells, and bacteria within some structured communities may be killed less efficiently than rapidly dividing laboratory cultures. Cell death is not adequately explained by a single universal sequence, and visible lysis is not required for every lethal effect.\n\nSelectivity does not mean that every bacterium is susceptible. Organisms lacking peptidoglycan, such as Mycoplasma, have no corresponding cell-wall target. Other organisms possess the target but restrict drug access or express poorly inhibited PBPs. Human cells lack peptidoglycan, explaining much of the class’s favorable selective toxicity, but adverse reactions can still arise through immune recognition, effects on the microbiota, or drug accumulation in particular tissues."
    },
    {
      "heading": "Principal drug families",
      "text": "Penicillins share the penam nucleus but differ substantially in their side chains. Natural penicillins include benzylpenicillin, also called penicillin G, and phenoxymethylpenicillin, or penicillin V. Antistaphylococcal penicillins, including oxacillin, nafcillin, and flucloxacillin, resist many staphylococcal penicillinases. Aminopenicillins, notably ampicillin and amoxicillin, extend activity to additional organisms. Antipseudomonal penicillins include piperacillin, which is commonly formulated with the beta-lactamase inhibitor tazobactam. These categories describe useful tendencies rather than interchangeable clinical properties.\n\nCephalosporins are often grouped into “generations,” a convention reflecting broad patterns of spectrum and development rather than a strict chemical or universal chronological classification. First-generation agents such as cefazolin and cephalexin have prominent activity against susceptible staphylococci and streptococci. Second-generation agents include cefuroxime; cefoxitin and cefotetan are chemically cephamycins but are often discussed alongside this generation. Third-generation agents include cefotaxime, ceftriaxone, and ceftazidime. Ceftazidime has antipseudomonal activity but weaker activity against many Gram-positive organisms than several other cephalosporins.\n\nCefepime, commonly designated fourth generation, combines antipseudomonal activity with activity against many organisms producing certain chromosomal beta-lactamases. Ceftaroline and ceftobiprole are distinguished by activity against methicillin-resistant Staphylococcus aureus through binding to its altered PBP. They are sometimes called fifth-generation cephalosporins, although terminology varies. Generation labels do not reliably convey activity against every pathogen: neither ceftriaxone nor cefepime is an anti-MRSA drug, and ceftaroline does not have dependable antipseudomonal activity.\n\nCarbapenems include imipenem, meropenem, ertapenem, and doripenem. They have broad activity against many Gram-positive, Gram-negative, and anaerobic bacteria, but important exceptions remain. Ertapenem lacks reliable activity against Pseudomonas aeruginosa, Acinetobacter species, and enterococci. Imipenem is administered with cilastatin, which inhibits its degradation by renal dehydropeptidase I; cilastatin is not itself an antibacterial beta-lactamase inhibitor.\n\nAztreonam is the principal established monobactam used systemically. Its activity is restricted to susceptible aerobic Gram-negative bacteria, including some P. aeruginosa, with no useful activity against Gram-positive organisms or anaerobes. More specialized agents include cefiderocol, a siderophore cephalosporin that exploits bacterial iron-transport systems. These examples show why an individual drug’s properties are more informative than the beta-lactam label alone."
    },
    {
      "heading": "Antibacterial spectrum and intrinsic limitations",
      "text": "Beta-lactam susceptibility reflects both the drug’s affinity for bacterial targets and its ability to reach those targets without being destroyed. The distinction between Gram-positive and Gram-negative bacteria is particularly important. Gram-positive organisms have a thick peptidoglycan layer outside the cytoplasmic membrane, whereas Gram-negative organisms possess an additional outer membrane. In the latter, many beta-lactams must pass through porin channels to enter the periplasm, where PBPs and many beta-lactamases are located.\n\nNarrow-spectrum penicillin retains activity against many streptococci and against Treponema pallidum, the cause of syphilis. Most contemporary S. aureus isolates produce penicillinase, making ordinary penicillin ineffective against them. Methicillin-susceptible S. aureus can remain susceptible to antistaphylococcal penicillins and cefazolin, whereas methicillin-resistant strains possess a target alteration that defeats most conventional beta-lactams. The term “methicillin resistance” persists even though methicillin itself is rarely used clinically.\n\nEnterococci illustrate another limitation. They are intrinsically resistant to cephalosporins, while susceptibility to ampicillin varies by species and strain. Enterococcus faecalis is commonly more susceptible than E. faecium. Listeria monocytogenes likewise has poor susceptibility to cephalosporins despite being a Gram-positive organism; ampicillin has an established role against it. Thus, Gram reaction alone cannot define an appropriate antibacterial spectrum.\n\nAmong Gram-negative bacteria, susceptibility varies greatly within Enterobacterales and nonfermenting organisms. Ceftriaxone is active against many susceptible Enterobacterales but not P. aeruginosa. Ceftazidime, cefepime, certain penicillins, and selected carbapenems can have antipseudomonal activity, but resistance within this species is common and mechanistically diverse. Activity against anaerobes also varies: some penicillin–inhibitor combinations and carbapenems cover many clinically important anaerobes, whereas aztreonam does not.\n\nThe class is generally unsuitable for organisms without a conventional accessible peptidoglycan target, including mycoplasmas. It also does not provide reliable coverage for several intracellular respiratory pathogens commonly grouped as “atypical,” including Chlamydia pneumoniae and Legionella pneumophila. Beta-lactams have no direct activity against viruses. These boundaries are clinically important because syndromes such as pneumonia can have bacterial, viral, or mixed causes that cannot be distinguished merely from the name of the syndrome."
    },
    {
      "heading": "Resistance mechanisms and their spread",
      "text": "The most widespread resistance mechanism is production of a beta-lactamase, an enzyme that hydrolyzes the beta-lactam ring before the drug can effectively inhibit its target. These enzymes vary in substrate range. Some mainly destroy penicillins; others attack expanded-spectrum cephalosporins, carbapenems, or multiple families. The Ambler molecular classification separates beta-lactamases into classes A, B, C, and D. Classes A, C, and D use an active-site serine, whereas class B enzymes are metallo-beta-lactamases that require metal ions, usually zinc.\n\nExtended-spectrum beta-lactamases, or ESBLs, include many CTX-M enzymes and certain TEM and SHV variants. They can hydrolyze expanded-spectrum cephalosporins and aztreonam, although their exact profiles differ. AmpC enzymes, categorized in class C, can be encoded chromosomally or carried on plasmids. In organisms such as Enterobacter cloacae complex, regulatory changes can produce high-level AmpC expression. This may alter susceptibility during exposure to particular beta-lactams.\n\nCarbapenemases include class A KPC enzymes, class B enzymes such as NDM, VIM, and IMP, and class D enzymes such as OXA-48-like carbapenemases. Their names do not imply identical activity against all beta-lactams. Metallo-beta-lactamases generally do not hydrolyze aztreonam, but organisms carrying them often possess additional enzymes that do. Carbapenem resistance can also arise without a carbapenemase, for example through a combination of reduced membrane permeability and production of other beta-lactamases.\n\nTarget modification provides a distinct route. In methicillin-resistant S. aureus, the commonly encountered mecA gene encodes PBP2a, a transpeptidase with low affinity for most beta-lactams. Altered PBPs also account for important resistance in pneumococci and other streptococci. In Gram-negative bacteria, loss or modification of porins reduces drug entry, and efflux systems can lower periplasmic drug concentrations. Several mechanisms often coexist within one isolate.\n\nResistance spreads both through selection of bacterial clones and through horizontal gene transfer. Plasmids, transposons, and other mobile genetic elements can carry beta-lactamase genes together with determinants affecting unrelated antibiotics. Resistance is distinct from tolerance, in which bacteria survive exposure longer without necessarily showing a higher minimum inhibitory concentration. These distinctions matter because a laboratory susceptibility result captures an important but incomplete part of the interaction among organism, drug, infection site, and bacterial physiological state."
    },
    {
      "heading": "Beta-lactamase inhibitors and combination agents",
      "text": "Beta-lactamase inhibitors protect a partner antibacterial drug from particular hydrolytic enzymes. They do not make every beta-lactam universally active, and their usefulness depends on the inhibitor’s enzyme coverage, the partner drug’s intrinsic spectrum, and other resistance mechanisms in the organism. The earliest widely used inhibitors—clavulanic acid, sulbactam, and tazobactam—are themselves beta-lactam compounds. Their established combinations include amoxicillin–clavulanate, ampicillin–sulbactam, and piperacillin–tazobactam.\n\nThese older inhibitors have useful activity against many class A enzymes, including common penicillinases, but provide unreliable protection against many AmpC enzymes and carbapenemases. Their effects also vary with enzyme quantity, bacterial burden, and the presence of multiple beta-lactamases. Consequently, apparent expansion of spectrum by an inhibitor cannot be inferred solely from the activity of a related combination or from a general label such as “ESBL-producing.”\n\nNewer inhibitors include compounds without a beta-lactam ring. Avibactam and relebactam are diazabicyclooctanes, while vaborbactam is a boronic acid derivative. Avibactam inhibits many class A and class C enzymes and some class D enzymes, including OXA-48-like enzymes, but not metallo-beta-lactamases. Vaborbactam has important activity against KPC enzymes, but not against metallo-beta-lactamases or OXA-48-like enzymes. Relebactam inhibits selected class A and C enzymes. Established pairings include ceftazidime–avibactam, meropenem–vaborbactam, and imipenem–cilastatin–relebactam.\n\nSulbactam is unusual because it has clinically relevant direct antibacterial activity against susceptible Acinetobacter through PBP binding. In sulbactam–durlobactam, the inhibitor durlobactam protects sulbactam from several enzymes produced by the organism. This differs conceptually from combinations in which the inhibitor has little direct antibacterial contribution and primarily protects a conventional penicillin, cephalosporin, or carbapenem.\n\nAztreonam provides another important mechanistic example. Its stability to metallo-beta-lactamases can be undermined by co-produced serine beta-lactamases; an inhibitor active against those additional enzymes can restore protection in some settings. Conversely, no inhibitor can reliably overcome resistance caused entirely by an inaccessible or poorly binding target. Resistance to newer combinations can emerge through altered beta-lactamases, changes in permeability, altered PBPs, or combinations of these processes. The relevant unit is therefore the specific drug–inhibitor–organism interaction rather than the inhibitor considered in isolation."
    },
    {
      "heading": "Pharmacokinetics and pharmacodynamics",
      "text": "Beta-lactams differ markedly in absorption, distribution, protein binding, and elimination. Some, including amoxicillin and cephalexin, are sufficiently absorbed for oral administration. Others are used mainly intravenously because gastrointestinal absorption is inadequate or because severe infection requires more predictable systemic exposure. Penicillin G is acid-labile, whereas penicillin V is more acid-stable. Long-acting intramuscular formulations, such as benzathine penicillin G, release drug slowly from an injection depot and produce a very different concentration profile from aqueous intravenous penicillin.\n\nMost beta-lactams are relatively hydrophilic and distribute predominantly through extracellular fluid. Penetration into particular compartments depends on molecular properties, protein binding, local blood flow, inflammation, and anatomical barriers. Passage into cerebrospinal fluid is limited for many agents by the blood–brain barrier, although meningeal inflammation increases penetration of some drugs. High concentrations in blood do not automatically establish adequate exposure in the central nervous system, bone, an abscess cavity, or an infected prosthetic device.\n\nThe central pharmacodynamic feature of most beta-lactams is time-dependent antibacterial activity. Their effect correlates particularly with the fraction of a dosing interval during which the unbound drug concentration exceeds the organism’s minimum inhibitory concentration:\n\n\\[fT_{>\\mathrm{MIC}} = \\frac{\\text{time during which unbound concentration exceeds MIC}} {\\text{dosing interval}} \\times 100\\%.\\]\n\nThe minimum inhibitory concentration, or MIC, is measured under standardized laboratory conditions. Experimental exposure targets vary among penicillins, cephalosporins, and carbapenems, and targets used in severe clinical infection may differ from those derived from animal models. There is no single universally applicable percentage for the entire class.\n\nThis exposure–response relationship explains interest in extended and continuous intravenous infusions. Such administration can maintain concentrations above the MIC for longer than a short infusion, especially when clearance is high or the organism’s MIC is near the susceptibility threshold. Whether an infusion strategy improves a particular outcome also depends on loading exposure, solution stability, access arrangements, pathogen distribution, and the clinical population studied.\n\nRenal elimination is important for many members of the class. Reduced kidney function can prolong exposure, while augmented renal clearance during critical illness can reduce it. Expanded extracellular fluid volume, burns, and kidney replacement therapy further alter pharmacokinetics. Important exceptions include substantial biliary elimination of ceftriaxone. Measurement of drug concentrations is used in some specialist settings, but availability and validated exposure targets vary."
    },
    {
      "heading": "Clinical roles and microbiological assessment",
      "text": "Beta-lactams have established roles across a wide range of infections, but the class is not a single interchangeable treatment. Examples include penicillin for susceptible streptococcal infection and syphilis, aminopenicillins for selected respiratory and enterococcal infections, and cephalosporins for particular forms of bacterial meningitis, gonorrhea, and bloodstream infection. Antipseudomonal agents and carbapenems have roles in serious infections caused by susceptible Gram-negative organisms. The specific pathogen, infection site, resistance profile, and drug exposure determine the relevance of each agent.\n\nTheir use in sepsis reflects the need for active antibacterial exposure during severe systemic infection. Initial treatment is often based on the suspected source and expected organisms before microbiological identification is complete. Subsequent organism identification and susceptibility results can substantially change the interpretation of that initial coverage. The term “broad-spectrum” describes the range of potentially susceptible organisms, not a guarantee of clinical effectiveness or superiority.\n\nBeta-lactams are also important in perioperative infection prevention. Cefazolin is widely used for prophylaxis in many types of surgery because of its activity against common skin organisms and its pharmacological properties. Other procedures involve different expected flora, including bowel anaerobes. Prophylaxis differs from treatment of established infection in its purpose, timing, and duration; prolonged exposure does not simply provide proportionally greater protection.\n\nLaboratory assessment includes culture, organism identification, disk diffusion, broth microdilution, and automated susceptibility systems. Clinical breakpoints classify results using MICs or inhibition-zone diameters together with achievable exposure and clinical evidence. Standards bodies, including the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing, periodically revise these criteria. Their categories and terminology are not identical, so a susceptibility label must be understood within its testing framework.\n\nMolecular tests can identify selected resistance genes rapidly, but absence of a tested gene does not prove susceptibility, and detection of a gene does not fully describe its expression or the contribution of other mechanisms. Laboratory methods may also show an inoculum effect, in which a larger bacterial population produces a higher measured MIC for some drug–organism combinations. Clinical outcome additionally depends on host defenses and control of the infection source. An obstructed infected urinary tract, an abscess, or an infected device can present problems that antibacterial activity alone does not resolve."
    },
    {
      "heading": "Adverse effects and immune-mediated reactions",
      "text": "Beta-lactams have a generally favorable therapeutic margin, but their adverse effects range from mild gastrointestinal symptoms to uncommon life-threatening reactions. Allergy is particularly important because the drug or its degradation products can bind to proteins and create structures recognized by the immune system. Immediate reactions can involve drug-specific IgE and manifest as urticaria, angioedema, bronchospasm, or anaphylaxis. Delayed reactions include uncomplicated exanthems as well as rare severe syndromes involving skin, mucosa, or internal organs.\n\nA recorded “penicillin allergy” is not synonymous with persistent, immunologically confirmed allergy. Some labels arise from childhood rashes associated with infection, nonallergic adverse effects, or incompletely documented events. Drug-specific IgE can also diminish over time. Clinical allergy evaluation may use a detailed history, appropriately selected skin testing, and supervised drug challenge in defined circumstances. These procedures address different levels and types of risk; a negative assessment for an immediate reaction does not exclude every possible delayed immune reaction.\n\nCross-reactivity is not determined solely by possession of the beta-lactam ring. Similar side chains, particularly the cephalosporin R1 side chain, are important determinants of recognition. Consequently, cross-reactivity differs between individual penicillins and cephalosporins rather than following one fixed rate for both families. Aztreonam generally has little immunological cross-reactivity with penicillins, but it shares a side-chain structure with ceftazidime, creating a notable exception. Severe delayed hypersensitivity requires separate consideration from an uncomplicated remote rash.\n\nNonallergic adverse effects include diarrhea, nausea, and changes in the intestinal microbiota. As with other antibacterial drugs, disruption of colonization resistance can contribute to infection with *Clostridioides difficile*. Some agents can cause liver injury, interstitial nephritis, cytopenias, or immune-mediated hemolytic anemia. Ceftriaxone can form calcium-containing precipitates and is associated with biliary sludge; specific precipitation hazards are particularly relevant in neonates.\n\nNeurotoxicity can occur when exposure is excessive, especially with impaired renal elimination. Manifestations include altered mental status, myoclonus, and seizures, with cefepime and imipenem among the agents for which this is well recognized. Carbapenems also markedly lower valproate concentrations, an interaction relevant to seizure control. These effects illustrate that favorable selective toxicity at the bacterial target does not remove the importance of host physiology, concomitant drugs, and agent-specific properties."
    },
    {
      "heading": "Manufacturing, stewardship, and continuing research",
      "text": "Modern beta-lactam production combines microbial fermentation, chemical synthesis, and enzymatic processing. Fermentation yields natural antibiotics or intermediates that can be converted into semisynthetic products. Penicillin acylases and related biocatalysts enable removal or attachment of side chains under controlled conditions. Production must preserve a chemically reactive ring while controlling impurities, residual solvents, potency, and degradation products. Some agents are unstable in aqueous solution, making storage temperature and the period after reconstitution important pharmaceutical variables.\n\nSensitization hazards also shape industrial organization. Beta-lactam manufacturing requires stringent measures against occupational exposure and cross-contamination of other medicines. At the same time, dependence on specialized production facilities and globally distributed supply chains can make shortages clinically consequential. A shortage of one agent is not always resolved by substituting another member of the class, because spectrum, formulation, tolerability, and tissue penetration may differ.\n\nAntimicrobial stewardship concerns the preservation of antibacterial effectiveness while maintaining effective treatment of infection. For beta-lactams, relevant activities include matching spectrum to microbiological evidence, interpreting allergy labels accurately, reviewing treatment duration, and monitoring local resistance. These are linked to infection prevention, diagnostic capacity, and access to quality-assured medicines. Resistance selection occurs not only in the infecting organism but also among other bacteria exposed in the patient’s microbiota and in wider ecological settings.\n\nResearch addresses several distinct problems. Siderophore conjugation, exemplified by cefiderocol, seeks to exploit bacterial iron uptake to improve entry across the Gram-negative outer membrane. New beta-lactamase inhibitors expand coverage against selected enzyme families. Structural studies of PBPs and beta-lactamases guide modifications intended to improve target binding or avoid hydrolysis. Experimental approaches also investigate combinations directed at multiple PBPs, potentially creating effects not achieved by either agent alone.\n\nImportant uncertainties remain in translating molecular activity into clinical benefit. Metallo-beta-lactamases, simultaneous resistance mechanisms, bacterial heterogeneity, and altered drug exposure in critical illness complicate development and evaluation. Comparative trials are particularly difficult when resistant infections are uncommon, geographically clustered, or caused by organisms with different resistance combinations. Surveillance therefore complements clinical trials by tracking emerging phenotypes and resistance genes. The continuing development of beta-lactams depends on integrating medicinal chemistry, bacterial genetics, reliable susceptibility testing, and the measurement of clinically meaningful outcomes."
    }
  ],
  "links": [
    "penicillin",
    "bacteria",
    "infectious-disease",
    "antibiotic-resistance",
    "alexander-fleming",
    "world-war-ii",
    "nobel-prize-in-physiology-or-medicine",
    "peptidoglycan",
    "amoxicillin",
    "gram-stain",
    "syphilis",
    "pneumonia",
    "beta-lactamase",
    "horizontal-gene-transfer",
    "blood-brain-barrier",
    "central-nervous-system",
    "pharmacodynamics",
    "minimum-inhibitory-concentration",
    "kidney",
    "pharmacokinetics",
    "sepsis",
    "surgery",
    "allergy",
    "immune-system",
    "urticaria",
    "anaphylaxis",
    "diarrhea"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}